Abstract 1995P
Background
Contemporary, real-world data on eligible pts receiving systemic tx following progression on first-line (1L) mUC therapy are needed to inform tx algorithms and identify potential gaps in the mUC care pathway. The objective of this analysis was to determine the prevalence and predictors of 2L tx receipt in pts with mUC in Germany.
Methods
This study identified adults with incident mUC (ICD-10 C65-68 and C77-79) from Jan 2015 to Jun 2021, using data from 2 statutory health insurance claims databases (Jan 2013-Jun 2022; ≈8 million pts). Pts were observed for ≥12 mo post incident mUC diagnosis (index) or until death. Baseline (BL) characteristics were identified 24 mo before index, and multivariable logistic regression analyzed factors associated with receiving 2L tx.
Results
Of 4,290 pts with mUC who were identified, 1,779 (41.5%) received 1L tx (mean age, 69.1 y; male, 74.2%; mean Charlson Comorbidity Index [CCI] score, 5.6; mean follow-up [FU], 19.6 mo). Of these pts, 699 (39.3%) received 2L tx (mean age, 67.6 y; male, 75.3%; mean CCI score, 5.3; mean FU, 22.8 mo). The number of pts with incident mUC who received 2L tx increased over time (index year 2015: 78 pts [11.2%]; 2020: 132 pts [18.9%]). The most common 2L txs were immune checkpoint inhibitors (462 pts [66.1%]), followed by non–platinum-based chemotherapy (non-PBC) in 121 pts (17.3%), and PBC in 116 pts (16.6%). Younger pts and those without other primary malignancies at BL were more likely to receive 2L tx (Table).
Conclusions
A high proportion of pts (60.7%) did not receive 2L tx. Pts who received 2L tx were generally younger and healthier with slightly lower CCI scores and fewer non-UC primary malignancies. Tx rates may be underestimated due to the potential for unaccounted txs from clinical trials. Further research is needed to clarify barriers to accessing 2L tx in this patient population. Table: 1995P
Factors associated with receiving 2L tx in pts with mUC
| Variable | Odds ratio (95% Cl) | p value |
| Age at index (continuous) | 0.98 (0.97-0.99) | Clinical trial identificationEditorial acknowledgementEditorial support was provided by Nucleus Global and was funded by Merck. Legal entity responsible for the studyMerck (CrossRef Funder ID: 10.13039/100009945), as part of a previous alliance between Merck and Pfizer. FundingThis study was sponsored by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945) and was previously conducted under an alliance between the healthcare business of Merck KGaA, Darmstadt, Germany and Pfizer. DisclosureG. Niegisch: Financial Interests, Personal, Invited Speaker: Roche, MEDAC, Pfizer, BMS, AstraZeneca, Astellas; Financial Interests, Personal, Advisory Board: Roche, Sanofi, BMS, Merck, Pfizer, Ipsen, Janssen; Financial Interests, Personal, Other, Travel, congress registrations: Roche, Pfizer, Merck. M. Kearney: Financial Interests, Personal, Full or part-time Employment: Merck ; Financial Interests, Personal, Stocks or ownership: Novartis, Merck, UCB. J. Krieger: Financial Interests, Personal, Full or part-time Employment: Cytel ; Financial Interests, Personal, Advisory Role: Merck. U. Osowski: Financial Interests, Personal, Full or part-time Employment: Merck Healthcare Germany GmbH, Weiterstadt, Germany, an affiliate of Merck KGaA; Financial Interests, Personal, Stocks/Shares: Merck. B. Deiters: Financial Interests, Personal, Full or part-time Employment: GWQ ServicePlus AG. U. Maywald: Financial Interests, Personal, Full or part-time Employment: AOK PLUS. T. Wilke: Financial Interests, Personal, Full or part-time Employment, Employment by IPAM, which received financial support from Cytel to conduct the claims data analyses: IPAM. M.J. Grimm: Financial Interests, Personal, Advisory Board: Astellas Pharma, AstraZeneca, Bayer/Vital, Bristol Myers Squibb, Eisai, Eusa Pharma, Gilead, Ipsen, MSD, Novartis, Pfizer, Roche Pharma AG, Takeda, Merck; Financial Interests, Personal, Other, travel, accommodations, and expenses: Bristol Myers Squibb, Merck; Financial Interests, Personal, Advisory Board, honoraria: Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eusa Pharma, Ipsen, MSD, Pfizer; Financial Interests, Personal, Research Funding: Bristol Myers Squibb, Intuitive Surgical. Resources from the same session1987P - TROP-2 as a promising ADC target in penile squamous cell carcinoma that promotes cell proliferation by activating AKT through PKCα pathwayPresenter: Yi Tang Session: Poster session 13 1988P - Enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE studyPresenter: Tanya Jindal Session: Poster session 13 1989P - Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysisPresenter: Albert Jang Session: Poster session 13 1990P - MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II studyPresenter: Chuanliang Cui Session: Poster session 13 1992P - Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (NAC)Presenter: Hedyeh Ebrahimi Session: Poster session 13 1993P - A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an optionPresenter: Anishka D'Souza Session: Poster session 13 1994P - Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in ≥ second line in metastatic urothelial carcinoma (mUC)Presenter: Bradley McGregor Session: Poster session 13 1996P - Primary analysis of post-marketing surveillance (PMS) data for avelumab maintenance therapy in patients (pts) with curatively unresectable urothelial carcinoma (UC) in JapanPresenter: Eiji Kikuchi Session: Poster session 13 1997P - Novel biomarker, ephrinB2 (B2), predicts resistance to treatment and poor overall survival (OS) metastatic urothelial carcinoma (mUC)Presenter: Sarmad Sadeghi Session: Poster session 13 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|